Health Technology Assessment per il Point of Care Testing e il concetto di Value- Based Healthcare nei laboratori clinici

AUTORI

ABSTRACT

Health Technology Assessment for Point of Care Testing and the concept of Value-based Healthcare in clinical la-boratories

Point of Care Testing has revolutionized the field of medical diagnostics, allowing tests to be performed outside traditional clinical laboratories. However, to ensure the effectiveness and safety of these technologies, rigorous evaluation through Health Technology Assessment (HTA) is essential. This assessment evaluates different aspects, including the clinical, economic, social, and organizational impact of new technologies, providing a multidisciplinary and quantitative framework to support evidence-based decisions. Moreover, integrating the concept of Value-Based Healthcare (VBHC) in clinical laboratories represents a paradigm shift, moving the focus from the volume of tests performed to the quality and effectiveness of the results obtained. This approach encourages laboratories to adopt tests that provide relevant and timely clinical information, thereby improving the patient care pathway. It implies the adoption of strategies that consider the quality of the tests and their effectiveness in the clinical context. Examples of HTA evaluation in Italy include the COVIDIAGNOSTIX project, which evaluated diagnostic devices for SARS-CoV-2 diagnosis, and the study on biomarkers for mild traumatic brain injury. These studies highlight the importance of HTA in ensuring that adopted technologies are effective, safe, and cost-efficient, supporting the transformation of clinical laboratories towards a value-based model. In conclusion, the adoption of VBHC and the integration of HTA are fundamental to optimizing clinical outcomes and ensuring the efficient use of healthcare resources in clinical laboratories, contributing to the overall improvement of diagnostic and therapeutic interventions.

BIBLIOGRAFIA

1. Plebani M, Nichols JH, Luppa PB, Greene D, Sciacovelli L, Shaw J, et al. Point-of-care testing: state-of-the art and perspectives. Clin Chem Lab Med 2024 doi: 10.1515/cclm-2024-0675 (ahead of print).
2. Nichols JH. Utilizing Point-of-Care Testing to Optimize Patient Care. EJIFCC 2021;32:140-4.
3. Stavelin A, Sandberg S. Analytical performance specifications and quality assurance of point-of-care testing in primary healthcare. Crit Rev Clin Lab Sci 2024;61:164-77.
4. Banfi G, Božič B, Cihan M, Pašalić D, Pennestrì F, Plebani M. Point-of-care testing, near-patient testing and patient self-testing: warning points. Clin Chem Lab Med 2024 doi:10.1515/cclm-2024-0525 (ahead of print).
5. Ferraro S, Biganzoli EM, Castaldi S, Plebani M. HealthTechnology Assessment to assess the value of biomarkers in the decision- making process. Clin Chem Lab Med 2022;60:647–54
6. EunetHTA-EunetHTA Joint Action 2 Work Package 8 HTA Core Model Version 3.0 for the full assessment of Diagnostic Technologies, Medical and Surgical Interventions, Pharmaceuticals and Screening Technologies 2016. https://www.eunethta.eu (ultimo accesso: luglio 2024)
7. Ritrovato M, Faggiano FC, Tedesco G, Derrico P. Decision-Oriented Health Technology Assessment: one step forward in supporting the decision-making process in hospitals. Value Health 2015;18:505-11
8. Andellini M, Faggiano F, Picardo SG, Testa G, Perrotta D, Bianchi R, et al. Health Technology Assessment of intensive care ventilators for pediatric Patients. Children. 2021;8:986
9. Teisberg E, Wallace S, O’Hara S. Defining and Implementing Value-Based Health Care: A Strategic Framework. Acad Med 2020;95:682-5.
10. Zanotto BS, Etges APBDS, Marcolino MAZ, Polanczyk CA. Value-Based Healthcare initiatives in practice: a systematic review. J Healthc Manag 2021;66:340-65.
11. Lawrence P. Value-based healthcare: a patient-centred approach. Br J Community Nurs 2022;27(Sup10):S5.
12. Pennestrì F, Banfi G. Value-based healthcare: the role of laboratory medicine. Clin Chem Lab Med 2019;57:798-801.
13. Arshoff L, Hoag G, Ivany C, Kinniburgh D. Laboratory medicine: The exemplar for value-based healthcare. Healthc Manage Forum 2021;34:175-80.
14. Tomaiuolo R, Banfi G. From volume to value: a watershed moment for the clinical laboratory. Clin Chem Lab Med 2023;62:593-6.
15. Daniels K, van der Voort MBV, Biesma DH & van der Nat Paul B. Five years’ experience with value-based quality improvement teams: the key factors to a successful implementation in hospital care. BMC Health Services Research 2022; 22:1271
16. https://eur-lex.europa.eu/homepage.html?locale=it (ultimo accesso: Luglio 2024).
17. Pisapia A, Banfi G, Tomaiuolo R. The novelties of the regulation on health technology assessment, a key achievement for the European union health policies. Clin Chem Lab Med 2022;60: 1160-3.
18. https://www.salute.gov.it/portale/dispositiviMedici/dettaglioContenutiDispositiviMedici. jsp?lingua=italiano&id=5201&area=dispositivi-medici&menu=tecnologie (ultimo accesso luglio 2024)
19. Pecoraro V, Germagnoli L, Banfi G. Point of care testing: where is the evidence? A systematic review. Clin Chem Lab Med 2014;52:313-24.
20. https://www.cadth.ca/sites/default/files/pdf/OP0519_POC_Troponin_Report.pdf
21. Kip MMA, Koffijberg H, Moesker MJ, IJzerman MJ, Kusters R. The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care. BMC Cardiovasc Disord 2017;17:213
22. Scandrett K, Colquitt J, Court R, Whiter F, Shinkins B, Takwoingi Y, et al. Evidence review for rapid tests to inform triage and antibiotic prescribing decisions: Suspected acute respiratory infection in over 16s: assessment at first presentation and initial managemenondon: National Institute for Health and Care Excellence (NICE); 2023 Oct. NICE Evidence Reviews Collection: National Institute for Health and Care Excellence (NICE); 2023. (NICE Guideline, No. 237.) disponibile su https://www.ncbi.nlm.nih.gov/ books/NBK598986/ (ultimo accesso: Luglio 2024).
23. Conrads-Frank A, Schnell-Inderst P, Neusser S, Hallsson LR, Stojkov I, Siebert S, et al. Decision-analytic modeling for early health technology assessment of medical devices – a scoping review. Ger Med Sci 2022;20:11
24. Tummers M, Kværner K, Sampietro-Colom L, Siebert M, Krahn M, Melien Ø, et al. On the integration of early health technology assessment in the innovation process: reflections from five stakeholders. Int J Technol Assess Health Care 2020;36:481-5.
25. Wang Y, Rattanavipapong W, Teerawattananon Y. Using health technology assessment to set priority, inform target product profiles, and design clinical study for health innovation. Technol Forecast Soc Change 2021172:121000.
26. Ettinger S, Jeindl R., Erdös J. Biomarkers in Alzheimer´s Disease. HTA-Information Service Rapid Review No.: 004; 2023. Vienna: HTA Austria – Austrian Institute for Health Technology Assessment https://eprints.aihta.at/1471/1/ HTA-Informationsdienst_Rapid_Review_004.pdf (ultimo accesso: Luglio 2024)
27. Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment. Ont Health Technol Assess Ser 2023; 23:1–146
28. Tomaiuolo R, Derrico P, Ritrovato M, Locatelli M, Milella F, Restelli U, et al. COVIDIAGNOSTIX: health technology assessment of serological tests for SARS-CoV-2 infection. Int J Technol Assess Health Care 2021;37:e87.
29. Colombini A, Viganò M, Tomaiuolo R, Di Resta C, Corea F, Sabetta E, et al. Exploratory assessment of serological tests to determine antibody titer against SARS-CoV-2: appropriateness and limits. J Clin Lab Anal 2022;36:e24363.
30. Tomaiuolo R, Restelli U, Faggiano FC, Di Resta C, Al Bitar Nehme S, Giuliani F, et al. Health technology assessment to employ COVID-19 serological tests as companion diagnostics in the vaccination campaign against SARSCoV- 2. Clin Chem Lab Med 2022;60:1463-77.
31. Tomaiuolo R, Di Resta C, Viganò M, Banfi G, Russo C, Linardos G, et al. Six months SARS-CoV-2 serology in a cohort of mRNA vaccinated subjects over 90 years old. Sci Rep 2022:12446.
32. Colombini A, Divieto C, Tomaiuolo R, Mortati L, Petiti J, Di Resta C, et al. The total testing process harmonization: the case study of SARS-CoV-2 serological tests. Clin Chem Lab Med 2023;61:2084-93.
33. Colombini A, Viganò M, Tomaiuolo R, Di Resta C, Corea F, Sabetta E, et al. Exploratory assessment of serological tests to determine antibody titer against SARS-CoV-2: Appropriateness and limits. J Clin Lab Anal 2022;36:e24363.
34. Ferrari D, Clementi N, Spanò SM, Albitar-Nehme S, Ranno S, Colombini A, et al. Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. Clin Chim Acta 2021;522:144-51.
35. Zibetti M, Di Resta C, Banfi G, Tomaiuolo R. Value-Based Health Care Implementation: The Case Study of mTBI Biomarkers. J Pers Med 2024;14:634.
36. Tomaiuolo R, Zibetti M, Di Resta C, Banfi G. Challenges of the Effectiveness of Traumatic Brain Injuries Biomarkers in the Sports-Related Context. J Clin Med 2023;12:2563.
37. Links between accuracy and effectiveness of laboratory medicine equipment: use of the EuNetHTA core model to compare two analyzers by measuring HBA1C. Int J Tech Assess Health Care (accepted, in press)